Allarity closes $20M non-convertible debt with Streeterville; extends cash runway to mid-2028

Allarity Therapeutics, Inc.

Closed $20M non-convertible debt financing with Streeterville Capital via two promissory notes: $10.93M and $10M.
Net proceeds extend cash runway into summer 2028; funds Phase 2 ovarian cancer trial and FDA preparation.
Proceeds also support pivotal trial prep, companion diagnostic strategy, and potential expansion into other WNT-driven tumors.
Stenoparib has shown durable clinical benefit; some patients on therapy >30 months in Phase 2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.